Egrifta (Tesamorelin Acetate) Market Report 2026

Egrifta (Tesamorelin Acetate) Market Overview

• The Egrifta (Tesamorelin Acetate) market growth in the historic period has been driven by rising incidence of hiv-associated lipodystrophy, long-term antiretroviral therapy side effects • Market expansion is supported by growth in personalized hiv care, pipeline expansion for peptide therapeutics • Growth Driver: Rising HIV Prevalence Fuels Growth In The Egrifta (Tesamorelin Acetate) Market • Market Trend: Resumption Of Synthetic Peptide Drug Production And Supply Management In The HIV-Related Lipodystrophy Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Egrifta (Tesamorelin Acetate) Market?

Egrifta (tesamorelin acetate) is a synthetic peptide that reduces excess abdominal fat in HIV patients with lipodystrophy by stimulating growth hormone release. It acts as a growth hormone-releasing hormone (GHRH) analog to target and decrease visceral fat. By promoting fat breakdown, it improves fat distribution and reduces health risks associated with abdominal fat. The main clinical indications for egrifta (tesamorelin acetate) are human immunodeficiency virus (HIV)-associated lipodystrophy, growth hormone deficiency, abdominal obesity, and metabolic syndrome. HIV-associated lipodystrophy is a condition in individuals with HIV characterized by abnormal fat distribution, including fat loss from limbs and excess fat accumulation in the abdomen. It is distributed through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels, and used by several end users, such as hospitals, specialized clinics, and home care.

What Is The Egrifta (Tesamorelin Acetate) Market Growth Forecast?

The growth in the forecast period can be attributed to growth in personalized hiv care, pipeline expansion for peptide therapeutics, increasing diagnosis of metabolic complications, supportive reimbursement for specialty drugs, focus on long-term quality of life in hiv patients. Major trends in the forecast period include long-acting peptide therapies, personalized lipodystrophy treatment, expansion of metabolic indications, patient-centric injectable therapies, specialty biologic drug adoption.

Global Egrifta (Tesamorelin Acetate) Market Segmentation

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 3) By End-Users: Hospitals, Specialized Clinics, Home Care

What Is The Driver Of The Egrifta (Tesamorelin Acetate) Market?

The increasing prevalence of human immunodeficiency virus (HIV) cases is significantly driving the growth of the egrifta (tesamorelin acetate) market in the future. Human immunodeficiency virus (HIV) cases refer to situations where individuals are infected with HIV, gradually weakening their immune system. The rise of HIV is partly due to insufficient awareness and education about preventive measures, such as condom use and regular testing, particularly in high-risk populations. Egrifta stimulates the release of growth hormone, which helps decrease excess visceral fat and improve body composition, ultimately boosting the overall health and quality of life for individuals with HIV. For instance, in May 2024, according to the Minnesota Department of Health, a US-based state health agency, in 2023, MDH reported 324 new HIV diagnoses, marking a 24% rise from 2022. Thus, the increasing prevalence of human immunodeficiency virus (HIV) cases is driving the growth of the egrifta (tesamorelin acetate) industry.

Key Players In The Global Egrifta (Tesamorelin Acetate) Market

Major companies operating in the egrifta (tesamorelin acetate) market are Theratechnologies Inc.

Global Egrifta (Tesamorelin Acetate) Market Trends and Insights

The key trend in the egrifta (tesamorelin acetate) market is focusing on developing advanced synthetic peptide drugs to enhance the effectiveness of treatments for HIV-related lipodystrophy. Synthetic peptide drugs are artificially designed compounds that aim to deliver specific therapeutic effects by mimicking or enhancing the action of naturally occurring peptides. For instance, in December 2024, Theratechnologies Inc., a Canada-based biopharmaceutical company, announced that production of EGRIFTA SV has resumed following a voluntary shutdown of its contract manufacturer’s facility due to FDA inspection observations. A newly manufactured batch has completed quality control and will be released upon US Food and Drug Administration (FDA) approval of a prior approval supplement, and two additional batches are in production. The company is managing inventory to meet patient demand until mid-January 2025 and is working with the FDA to prevent a shortage in 2025. EGRIFTA SV is distributed only in the United States.

What Are Latest Mergers And Acquisitions In The Egrifta (Tesamorelin Acetate) Market?

In January 2023, the World Orphan Drug Alliance (WODA), a Slovenia-based alliance of commercial distributors focused on providing access to treatments for rare diseases, announced a significant agreement with Theratechnologies for the distribution of EGRIFTA SV, a medication used to reduce excess visceral abdominal fat in adults living with HIV and lipodystrophy. This partnership aims to enhance the availability and accessibility of EGRIFTA SV, which is crucial for patients managing these conditions. Theratechnologies Inc. is a Canada-based pharmaceutical company that manufactures egrifta (tesamorelin acetate).

Regional Insights

North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Egrifta (Tesamorelin Acetate) Market?

The egrifta (tesamorelin acetate) market consists of sales of tesamorelin acetate injections and tesamorelin acetate vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Egrifta (Tesamorelin Acetate) Market Report 2026?

The egrifta (tesamorelin acetate) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the egrifta (tesamorelin acetate) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.